Literature DB >> 20978468

Management of cytomegalovirus infection in solid organ transplantation.

Camille N Kotton1.   

Abstract

Cytomegalovirus (CMV) infections are among the most common infections that occur following solid organ transplantation. CMV disease ranges from asymptomatic viremia, to CMV syndrome, to tissue-invasive disease. As CMV prophylaxis, treatment, diagnostics, and overall awareness have improved, the general trend has been towards earlier diagnosis of CMV disease and more mild clinical presentations in solid organ transplant recipients. Major stumbling blocks remain in the areas of duration of prophylaxis for the individual recipient, in the identification of which patients might need secondary prophylaxis, in the treatment of resistant virus, and in the possible use of the adoptive transfer of CMV-specific T cells. Several guidelines have been published during the past few years regarding the management of CMV in solid organ transplant recipients. This Review covers CMV diagnostics, methods for the prevention of CMV infection, treatment of both regular and drug-resistant CMV, as well as future directions for CMV management and research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978468     DOI: 10.1038/nrneph.2010.141

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  132 in total

Review 1.  Cytomegalovirus drug resistance and clinical implications.

Authors:  S W Chou
Journal:  Transpl Infect Dis       Date:  2001       Impact factor: 2.228

2.  Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.

Authors:  M Villa; E Lage; S Ballesteros; E Cañas; M Sánchez; A Ordóñez; J M Borrego; R Hinojosa; J M Cisneros
Journal:  Transplant Proc       Date:  2003-03       Impact factor: 1.066

3.  Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

Authors:  D Kumar; S Chernenko; G Moussa; I Cobos; O Manuel; J Preiksaitis; S Venkataraman; A Humar
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

4.  PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy.

Authors:  U Sester; D Presser; J Dirks; B C Gärtner; H Köhler; M Sester
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

5.  Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?

Authors:  R Corales; J Chua; S Mawhorter; J B Young; R Starling; J W Tomford; P McCarthy; W E Braun; N Smedira; R Hobbs; G Haas; D Pelegrin; M Majercik; K Hoercher; D Cook; R K Avery
Journal:  Transpl Infect Dis       Date:  2000-09       Impact factor: 2.228

6.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

Authors:  D Lowance; H H Neumayer; C M Legendre; J P Squifflet; J Kovarik; P J Brennan; D Norman; R Mendez; M R Keating; G L Coggon; A Crisp; I C Lee
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

Review 7.  Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

Authors:  Maher K Gandhi; Rajiv Khanna
Journal:  Lancet Infect Dis       Date:  2004-12       Impact factor: 25.071

8.  Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.

Authors:  Solbjørg Sagedal; Anders Hartmann; Knut P Nordal; Kåre Osnes; Torbjørn Leivestad; Aksel Foss; Miklos Degré; Per Fauchald; Halvor Rollag
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

9.  Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.

Authors:  G Gerna; D Lilleri; V Rognoni; M Agozzino; F Meloni; T Oggionni; C Pellegrini; E Arbustini; A M D'Armini
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

10.  Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients.

Authors:  A Humar; M Uknis; C Carlone-Jambor; R W Gruessner; D L Dunn; A Matas
Journal:  Transplantation       Date:  1999-01-15       Impact factor: 4.939

View more
  36 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.

Authors:  Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

Review 3.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

Review 4.  Precision Transplant Medicine: Biomarkers to the Rescue.

Authors:  Maarten Naesens; Dany Anglicheau
Journal:  J Am Soc Nephrol       Date:  2017-10-09       Impact factor: 10.121

5.  Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.

Authors:  R Bachmann; K Hamprecht; J Lange; R Ladurner; S Nadalin; G Jahn; A Königsrainer; A Heininger
Journal:  Infection       Date:  2013-04-02       Impact factor: 3.553

6.  Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.

Authors:  Tracy L Lemonovich; Richard R Watkins
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

7.  Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection.

Authors:  Davide Abate; Marta Fiscon; Alda Saldan; Simona Cofano; Carlo Mengoli; Dino Sgarabotto; Chiara d'Agostino; Luisa Barzon; Riccardo Cusinato; Giuseppe Toscano; Giuseppe Feltrin; Antonio Gambino; Gino Gerosa; Giorgio Palù
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

Review 8.  Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.

Authors:  Daniel S Owers; Angela C Webster; Giovanni F M Strippoli; Kathy Kable; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

9.  Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Authors:  Daniel C Freed; Qi Tang; Aimin Tang; Fengsheng Li; Xi He; Zhao Huang; Weixu Meng; Lin Xia; Adam C Finnefrock; Eberhard Durr; Amy S Espeseth; Danilo R Casimiro; Ningyan Zhang; John W Shiver; Dai Wang; Zhiqiang An; Tong-Ming Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

10.  Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Authors:  Lin Xia; Ruopeng Su; Zhiqiang An; Tong-Ming Fu; Wenxin Luo
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.